Connect your AI

Bicara Therapeutics BCAX Total

Total at other companies

AmgenAMGN

——

Arcus BiosciencesRCUS

——

Nuvation BioNUVB

——

Viridian Therapeutics, Inc.VRDN

——

BridgeBio PharmaBBIO

——

Natera, Inc.NTRA

——

Other financials

Income statement

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

Market cap$1.68B+81.4%

Returns & leverage

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's total.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bicara Therapeutics's total?: Bicara Therapeutics (BCAX) reported total of $216.53M in Q1 2026.